Value of serum calcitonin estimation in clinical oncology

Mulder, H.; Hackeng, W. H. L.; Silberbusch, J.; Ottolander, G. J. den; Meer, C. van der

doi:10.1038/bjc.1981.116

Cited by 8 publications

(2 citation statements)

References 12 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wallach et al [138] reported a decrease in serum CT levels in SCLC patients responding to chemotherapy, and an increase in progressive diseases. Mulder et al [140], on the contrary, reported no such effect. In conclusion, the assay of serum calcitonin seems to be a general indicator of the course of SCLC disease, but it is sufficiently reliable for evaluating the response to treatment.…”

Section: Hormones As Cancer Biomarkersmentioning

confidence: 80%

Serum-based protein biomarkers for detection of lung cancer

2014

View full text Add to dashboard Cite

Lung cancer is one of the most common cancers in terms of both incidence and mortality.The major reasons for the increasing number of deaths from lung cancer are late detection and lack of effective therapies. To improve our understanding of lung cancer biology, there is urgent need for blood-based, non-invasive molecular tests to assist in its detection in a cost-effective manner at an early stage when curative interventions are still possible. Recent advances in proteomic technology have provided extensive, high throughput analytical tools for identification, characterization and functional studies of proteomes. Changes in protein expression patterns in response to stimuli can serve as indicators or biomarkers of biological and pathological processes as well as physiological and pharmacological responses to drug treatment, thus aiding in early diagnosis and prognosis of disease. However, only a few biomarkers have been approved by the FDA to date for screening and diagnostic purposes. This review provides a brief overview of currently available proteomic techniques, their applications and limitations and the current state of knowledge about important serum biomarkers in lung cancer and their potential value as prognostic and diagnostic tools.

show abstract

Section: Hormones As Cancer Biomarkersmentioning

confidence: 80%

Serum-based protein biomarkers for detection of lung cancer

2014

View full text Add to dashboard Cite

show abstract

“…WALLACH et al [180] reported a decrease of CT serum levels in SCLC patients responding to chemotherapy, and an increase in progressive diseases. MULDER et al [182], on the contrary, showed no such effect.…”

Section: Calcitoninmentioning

confidence: 89%

Serum tumour markers in lung cancer: history, biology and clinical applications

Ferrigno¹,

Buccheri²,

Biggi³

1994

Eur Respir J

102

View full text Add to dashboard Cite

S Se er ru um m t tu um mo ou ur r m ma ar rk ke er rs s i in n l lu un ng g c ca an nc ce er r: : h hi is st to or ry y, , b bi io ol lo og gy y a an nd d c cl li in ni ic ca al l a ap pp pl li ic ca at ti io on ns s Several tumour markers have been studied in lung cancer. Unfortunately, none of these appear to be sufficiently sensitive and specific to be reliable for screening and diagnostic purposes. However, there is a body of evidence which proves that at least some of these substances may be useful in the evaluation of the course and prognosis of the disease.This review presents data concerning the most studied and interesting tumour markers in lung cancer.

show abstract

Present status of serum markers

Minton

Chevinsky

1989

Seminars in Surgical Oncology

View full text Add to dashboard Cite

Tumor markers presently in use generally meet only one or two of the criteria for the ideal marker, which are: tumor specificity, correlation with tumor bulk and stage of the disease, decrease to normal after successful treatment, and rise prior to clinical manifestations of recurrence. In addition, virtually all are elevated in some benign conditions. Currently their greatest usefulness is for confirmation of clinical suspicion and for monitoring known disease. Some tumor markers which are not effective as screening tests can be used to evaluate the patient's response to therapy. The discovery of oncogenes holds great promise for a new generation of tumor markers. Major breakthroughs in the fields of molecular biology and tumor immunology seem imminent with eventual application possibly in the treatment of cancer.

show abstract

Value of serum calcitonin estimation in clinical oncology

Cited by 8 publications

References 12 publications

Serum-based protein biomarkers for detection of lung cancer

Serum-based protein biomarkers for detection of lung cancer

Serum tumour markers in lung cancer: history, biology and clinical applications

Present status of serum markers

Contact Info

Product

Resources

About